FDA EIR - California Cryobank LLC - September 12, 2007

An FDA inspection of California Cryobank, Inc. in Los Angeles, CA, was conducted from September 6-12, 2007. The inspection focused on the firm's operations involving Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), primarily semen donation and banking, under the regulatory framework of 21 CFR Part 1271. Notably, this inspection did not result in any formal observations or an FDA Form 483 being issued.

However, several discussion items were raised with management for improvement. These included enhancing the clarity of procedures for medical director designees, specifically regarding their qualifications and the review of communicable disease test results, and ensuring appropriate provision of confidential donor information. The inspection also highlighted the need to revise the Adverse Reaction Standard Operating Procedure (SOP) to incorporate communicable diseases and outline reporting requirements for serious adverse events to the FDA. Additionally, management was advised to develop a specific procedure for Biological Product Deviation Reporting and to expand the existing Recall SOP to include clear guidance on communicable disease-related recalls and end-user compliance. The absence of a contract agreement with a particular testing facility was also noted. Management committed to addressing these areas through procedural enhancements and developing new procedures. The firm had previously successfully implemented Standard Operating Procedures for remote blood draws, addressing an observation from a prior inspection.